Weekly Research Analysts’ Ratings Updates for Gilead Sciences (GILD)

Several analysts have recently updated their ratings and price targets for Gilead Sciences (NASDAQ: GILD):

• 10/20/2026 – Gilead Sciences had its price target raised by Bank of America Corporation from $168.00 to $172.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Gilead Sciences had its “buy” rating reaffirmed by Bank of America Corporation. They now have a $164.00 price target on the stock.
• 10/8/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $123.00 to $126.00. They now have a “sector perform” rating on the stock.
• 10/8/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 10/7/2026 – Gilead Sciences had its price target raised by Truist Financial Corporation from $150.00 to $158.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Gilead Sciences had its price target raised by JPMorgan Chase & Co. from $160.00 to $170.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $165.00 to $163.00. They now have an “overweight” rating on the stock.
• 9/29/2026 – Gilead Sciences was downgraded by Zacks Research from “strong-buy” to “hold”.
• 9/19/2026 – Gilead Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/14/2026 – Gilead Sciences was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/10/2026 – Gilead Sciences had its price target raised by HSBC Holdings plc from $155.00 to $175.00. They now have a “buy” rating on the stock.
• 9/5/2026 – Gilead Sciences was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/31/2026 – Gilead Sciences was upgraded by Zacks Research from “hold” to “strong-buy”.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date of this dividend was Tuesday, September 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.1%. Gilead Sciences’s dividend payout ratio (DPR) is currently -122.85%.

Insider Activity

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the chief financial officer owned 161,096 shares in the company, valued at approximately $25,166,417.12. This represents a 1.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 111,000 shares of company stock valued at $15,877,860. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.